Calamos Advisors’s Gilead Sciences GILD Stock Holding History

Calamos Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-235,000	Closed	-$605K	–	615
2017 Q3	$605K	Buy	+235,000	New	+$18M	﹤0.01%	554
2017 Q2	–	Sell	-1,900	Closed	-$551K	–	624
2017 Q1	$551K	Buy	+1,900	New	+$134K	﹤0.01%	563
2015 Q2	–	Sell	-1,650	Closed	-$804K	–	699
2015 Q1	$804K	Sell	1,650 -1,040	-39%	-$106K	0.01%	549
2014 Q4	$6.88M	Sell	2,690 -5,705	-68%	-$590K	0.05%	314
2014 Q3	$31.8M	Sell	8,395 -8,557	-50%	-$838K	0.21%	130
2014 Q2	$32.3M	Sell	16,952 -1,507	-8%	-$117K	0.2%	130
2014 Q1	$21M	Buy	18,459 +1,024	+6%	+$80.3K	0.13%	176
2013 Q4	$30.1M	Buy	17,435 +6,315	+57%	+$440K	0.19%	140
2013 Q3	$15.9M	Buy	11,120 +4,175	+60%	+$250K	0.1%	203
2013 Q2	$8.82M	Buy	+6,945	New	+$362K	0.06%	231

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Calamos Advisors's GILD Position: Q1 2026 in Review

Calamos Advisors increased its Gilead Sciences (GILD) stake by 83% in Q1 2026, buying an estimated $26.2M and bringing the position to 412,590 shares worth $57.5M. The position accounts for 0.2% of the portfolio, ranked #110.

Calamos Advisors first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $192M in Q2 2013. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Calamos Advisors held 412,590 shares of Gilead Sciences worth $57.5M as of Q1 2026.
Calamos Advisors bought 187,021 Gilead Sciences shares in Q1 2026, an estimated $26.2M.
Gilead Sciences made up 0.2% of Calamos Advisors's portfolio in Q1 2026, its #110 holding.
Calamos Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
Calamos Advisors's Gilead Sciences position peaked at $192M in Q2 2013.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.